Aprea

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision cancer therapeutics that exploit DNA damage response (DDR) pathways and tumor suppressor mutations. Originally pioneering the reactivation of mutant p53 — the most frequently mutated gene in human cancer, present in approximately 50% of all tumors — Aprea has expanded its pipeline to include multiple DDR-targeted small molecule inhibitors designed to selectively destroy cancer cells while minimizing toxicity to healthy tissue. Its lead compound, eprenetapopt (APR-246), received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for myelodysplastic syndromes (MDS). The company conducts clinical research with operations in Doylestown, Pennsylvania and is publicly traded on NASDAQ under the ticker APRE.